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The purpose of the thesis was to examine the importance of Supply Chain 
Management (SCM) in developing and delivering effective and sustainable sup-
ply chains and value chains in the Pharmaceutical Industry. In addition, it was a 
goal to gain an understanding of the likely future trends and threats to the indus-
try, and analyse how SCM can be used to address these. 
 
The information for the theoretical framework was gathered from academic 
books, sector specific articles and journals, and recent studies. The empirical 
part was based on two structured questionnaires which were sent to 20 Euro-
pean based multi-national pharmaceutical companies and 7 European national 
pharmaceutical trade associations. Unfortunately only one response was re-
ceived therefore, this company was used as a case study. For further analysis 
and formulation of recommendations the results from this response were com-
pared to results of previous research into the subject conducted by respected 
research companies.  
 
The results of the study show that sustainable SCM is of key importance to 
pharmaceutical companies and that they are taking actions to modernise their 
supply and value chains, so to deliver cost savings and value to both the com-
pany and the end-user. However, total sustainable SCM is not likely in the near 
future unless there is a move towards global consensus on legislation affecting 
the pharmaceutical industry. 
 
Keywords: Supply Chain Management (SCM), Supply Chain, Value Chain, 
Pharmaceutical Industry, Pharmaceutical Company 
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1 Introduction 
 
1.1 Background 
 
In the modern global market place, every company no matter its size, business 
type or location is faced with increasing customer demands, competition, and 
rising development costs. As a result companies have to explore new methods 
of business operation to remain competitive and profitable, whilst delivering 
what the end-user wants, when they want it, where they want it and at an af-
fordable price. As a means of doing this many companies are reviewing their 
supply and value chain management as a means of driving efficiency and deliv-
ering value. 
 
This issue is of particular relevance to the pharmaceutical industry which is 
characterised by long product development and lead times, multiple supply 
chain networks at different stages of product development, and whose end 
product(s) has a direct real life impact on the final customer. Sector commenta-
tors have also suggested that most pharmaceutical companies currently have 
supply chains that are neither flexible nor cost effective (PricewaterhouseCoop-
ers 2011, p. 3). This combined with reduced economies of scale that industry 
leaders previously enjoyed through the blockbuster drug “paradigm” due to the 
increase of generic competition, has led to many traditional Pharmaceutical 
Companies beginning to refine and redefine their supply and value chains, and 
their management. 
 
1.2 Research Objectives and Research Questions 
 
The objective of this study is to analyse the importance of Supply Chain Man-
agement (SCM) in developing and delivering effective and sustainable supply 
chains and value chains in the pharmaceutical industry. In addition, it is a goal 
of the thesis to examine the future trends and threats to the industry, and how 
SCM can be used to address these.  
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The thesis broaches the issue of the management of supply and value chains, 
in the Pharmaceutical Industry. Therefore the primary research question is: 
 
 How can the pharmaceutical industry achieve effective and sustainable (re-
sponsible) supply chain management? 
 
Furthermore, the sub research questions will support the study and they are as 
follows: 
 
 What do typical supply and value chains of pharmaceutical company’s look 
like? 
 What are the economic and commercial benefits of developing effective 
SCM to the pharmaceutical industry? 
 What are the most important payoffs of a more sustainable supply chain? 
 What are the key values of developing effective supply chains? 
 What are the biggest challenges/obstacles to successful SCM in the phar-
maceutical industry? 
 
These research questions will help the author to find an answer to whether ef-
fective SCM can be used as a tool for delivering competitive advantage and 
added value during a period of increased economic and operating difficulties, 
and to address future business challenges. 
 
1.3 Delimitations 
 
This research focuses on supply and value chains, and the development of 
SCM in pharmaceutical companies, and does not attempt to examine SCM in 
other business sectors as this would have made the research field too large, 
generalised and labour intensive in information gathering. It also only focuses 
on large multi-national pharmaceutical companies whose head offices are lo-
cated in the European Union (EU), and does not examine smaller generic drug 
manufacturers as they tend not to have such dispersed supply chains. This is 
because European Community Regulations on SCM and sustainability cover all 
7 
companies no matter where they are located within the Union, and therefore 
made the gathering and comparison of information easier because they all have 
to operate according to the same set of regulations where ever they are located 
within the EU. 
 
1.4 Research Method 
 
For the theoretical part about supply and value chains and SCM, sustainable 
SCM and supply and value chains in the pharmaceutical industry, the qualitative 
approach was chosen and thus the author gathered information from academic 
books, research papers and industry produced reports. Data was also acquired 
from internet sources, e.g. current figures of the size and value of the european 
pharmaceutical industry. The research methods of the empirical part are de-
scribed in chapter 6.1. 
 
2 Supply and Value Chains and SCM 
 
To understand the importance of effective and efficient supply and value chains 
in the pharmaceutical industry as a means of developing competitive advantage 
and improving returns on investment and profitability; it is important to establish 
a high level understanding of what a supply and value chain, and its associated 
activities entail and incorporate. 
 
The subject of supply and value chains and SCM is not a new one, and has 
been the subject of a number of academic studies and writings. However, its 
use as a tool for driving company differentiation, competitiveness and efficiency, 
whilst continuously delivering above and beyond the final customers’ expecta-
tions; is still a relatively new issue in terms of the business world. Modern SCM 
emerged in the 1990’s, and has been driven by a number of factors including 
the global nature of modern business operations, the growth of the internet, rap-
id advancement in technology, particularly in information technology; which has 
enabled companies to operate in real-time across large distances; a change in 
customer affluence, demands and sophistication, security threats and global 
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recessions. From this starting point it has rapidly grown and is now recognised 
as an essential factor in global competition. 
 
Supply chains and value chains can be understood to consist of a series of ac-
tivities and interactions in which a product or a material is transferred from its 
point of origin or source through the delivery to the end consumer. A value 
chain moves beyond the simple transferring of products, and includes the addi-
tion of certain values at various stages of its development in order to provide 
maximum satisfaction to the end consumer. The supply chain and the value 
chain are related to each other even though they move in opposite directions. 
Figure 1 provides an overview of this linkage. 
 
 
Figure 1. A comparison between a value chain and supply chain (Feller et al 
2006) 
 
From this simple diagram a supply chain can be said to be made up of a flow of 
products and services in one direction, whilst the flow of demand and cash in 
the other direction represents the value chain. This means that the primary dif-
ference between a supply chain and a value chain is a shift in focus from the 
supply base to the customer. In order for supply chains to be capable of gener-
ating maximum value, they must synchronise the flows of supply with the flows 
of value from customers in the form of rapidly shifting tastes, preferences, and 
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demand. Companies therefore need to stop viewing supply chains and value 
chains as different entities, but, rather, should integrate the two. (Feller et al 
2006.) Supply chains, value chains and their management (SCM) are discussed 
in more detail in the following sections of this report. 
 
2.1 Supply Chains 
 
There are many different definitions of the term “supply chain.” Typically a sup-
ply chain can be defined as a network of organisations that are involved, 
through upstream and downstream linkages, in the different processes and ac-
tivities that produce value in the form of products and services in the hands of 
the ultimate customer or consumer (Lysons & Farrington 2006, p. 93). The pro-
cesses involved in a supply chain may include activities such as sourcing raw 
materials and parts, producing or assembling the products, storing the products, 
order processing and tracking, through to the distribution and delivery of the 
product to the final customer (Sanders 2012, p. 3). Figure 2 provides an over-
view of a simplified supply chain. 
 
 
 
Figure 2. Simplified supply chain 
 
However, a supply chain is much more complex than this image suggests and 
is a complex network of different trading partners, typically referred to as stag-
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es; it includes suppliers, producers, wholesalers/distributors, retailers and cus-
tomers. It also important to bear in mind that no one supply chain is the same, 
and each stage may not be present in every supply chain. Supply chains are 
also coming under increased financial pressure, which has resulted in many 
companies reviewing their supply chains, and as a result the companies are 
bypassing or removing stages that are not delivering value. As a result supply 
chains are often referred to as a “value chain” or a “value network.” (Sanders 
2012, p. 4.) 
 
2.2 Value Chains/Value Network 
 
As mentioned in the previous section, supply chains are also commonly referred 
to as “value chains or networks,” and the effective management of Supply 
chains can be used as a tool for deriving better returns on investment and out-
lay on product development and other associated costings. A value chain can 
be viewed as a linear map of the means by which value is added through a pro-
cess from sourcing and processing of raw materials, to the assembly and deliv-
ery of the finished product to the end-user, including after delivery service (Ly-
sons & Farrington 2006, p. 101.) 
 
The most recognised and important value chain models have been developed 
by Michael Porter of the Harvard Business School, and Peter Hines of the Uni-
versity of Wales. In the 1980’s Michael Porter reasoned that a company’s’ com-
petitive advantage can only be understood by examining the costs that are cre-
ated by the individual departments or team within a company, and how their 
supply chain activities affect the company as a whole. The primary and second-
ary value chain activities described by Porter (1985) are indicated in Figure 2. 
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Figure 2. Michael Porter’s “Value Chain Model” (Saha 2011) 
 
Porter believes that business activities can be classified into five primary activi-
ties (inbound logistics, operations, outbound logistics, marketing and sales and 
service activities) and four supporting activities (firm infrastructure, human re-
source management, technology development and procurement activities); 
which if managed effectively can deliver a competitive advantage. The term 
“margin” is used to indicate that a company is able to make a profit that is more 
that than the combined cost of these activities (Lysons & Farrington 2006, p. 
102-103.) 
 
In 1993, Peter Hines published a critic on Porters original work which recog-
nised Porters model in that it helps to improve the strategy of managers in are-
as such as materials management and customer relations and retention, which 
were placed in a very important position within the company. However by focus-
ing primarily on profitability and profit generation, Porter fails to take into ac-
count the importance of consumer satisfaction. Porter’s model provides a divid-
ed network within the company and with its partners, rather than highlighting the 
importance of integration across the whole network. Finally, as Porter’s work 
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was based solely on American case studies his conclusions are not appropriate 
for modern day companies who are operating on an increasingly international 
playing field. To correct this Hines offers two models (1) “a micro integrated ma-
terial’s value pipeline” operating as one large flow pointing from consumer to 
raw materials source, based on a pull system process rather than a push pro-
cess suggested by Porter; and (2) “a macro ten forces partnership model”, in 
which teams are primarily concerned with marketing, materials, engineering, 
quality, R&D and design. Secondary activities include activity-based costing 
(ABC), HRM/training/education, Total Quality Management (TQM), Electronic 
Data Interchange (EDI) and profit. (Lysons & Farrington 2006, p. 103-104.) 
 
2.3 Supply Chain Management 
 
Imperative to efficient and effective supply and value chain is supply chain 
management (SCM). SCM means different things to different people, and there 
is not one clear definition as to what SCM is. However, it can be generally ac-
cepted that SCM involves the design, coordination and management of flows of 
products, information, and funds throughout the supply chain. The Council of 
Supply Chain Management Professional (CSCMP) states that 
 
“Supply chain management encompasses the planning and management of all 
activities involved in sourcing and procurement, conversion, and all logistics 
management activities. Importantly, it also includes coordination and collabora-
tion with channel partners, which can be suppliers, intermediaries, third party 
service providers, and customers. In essence, supply chain management inte-
grates supply and demand management within and across companies.” 
 
They additionally state that 
 
“Supply chain management is an integrating function with primary responsibility 
for linking major business functions and business processes within and across 
companies into a cohesive and high-performing business model. It includes all 
of the logistics management activities noted above, as well as manufacturing 
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operations, and it drives coordination of processes and activities with and 
across marketing, sales, product design, finance, and information technology.” 
 
SCM is therefore can be viewed as an integrating function with the primary ob-
jective of linking  major business functions and processes within and across 
companies and their partners, into a high-performing business model. It in-
cludes activities such as logistics management and manufacturing operations, 
and drives the coordination of processes across all business departments, 
thereby developing a more holistic approach to business operation rather than 
operating in silos. (Grant et al 2013, p. 3.)  
 
It can be concluded that SCM is about the companies collaborating to leverage 
strategic positioning and to improve operating efficiency (Bowersox, et al 2002, 
p. 4). This is increasingly being achieved through collaboration and partnership 
agreements, which bring their own difficulties, particularly when operating at a 
global level. As a consequence a collaborative supply chain strategy agreed, by 
all links in a supply chain is essential to achieve efficient and desired outcomes 
and to manage risks. 
 
2.4 Increasing Importance of SCM 
 
Modern SCM has can be traced back to the 1990’s when difficult global eco-
nomic conditions and an increase in uncertainty in business environments, 
made it necessary for companies to seek new ways of doing things. This has 
included activities such as customisation of products to customer specifications 
and reducing lead times between product design, manufacture and delivery to 
the customer; in order to make a profit and survive.  
 
SCM has increasingly proven to be an essential element for successful global 
competitiveness. A number of forces have given rise to this trend. Firstly, com-
panies have realised that they can make significant savings through planning 
and managing their supply chain activities better. Secondly, advances in tech-
nology, most notably the World-Wide-Web (WWW), have allowed companies 
access information critical to their business success, and to better manage their 
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supply chains, particularly as they becoming more international and widely 
spread. Thirdly, improved transportation methods have led to reductions in 
transport costs, whilst provided alternative and faster modes of transport than 
had previously been available. Finally, greater customer disposable income, 
sophistication and demands, has resulted in a greater variety of quality goods 
and services. (Sanders 2012, p. 15-17.) 
 
2.5 SCM and Logistics 
 
To this point this report has discussed SCM and supply chains. However, it is 
important to provide a definition of what is meant by the term “logistics,” as peo-
ple think that SCM and logistics is the same thing. The Council of Supply Chain 
Management Professional (CSCSP) succinctly summaries logistics manage-
ment as 
 
“… that part of supply chain management that plans, implements, and controls 
the efficient, effective forward and reverses flow and storage of goods, services 
and related information between the point of origin and the point of consumption 
in order to meet customers' requirements.” 
 
Logistics can be viewed as the work required to move and position inventory 
throughout a supply chain. However, logistics goes beyond transportation and it 
is a much more complex process, including issues such as planning and prepa-
ration; packaging; documentation; storage; insurance and import and export 
regulations. Logistics and logistics management can therefore be viewed as a 
supporting element of SCM, which is essential in ensuring that all links in a 
supply chain are joined up, and dictates how a SCM plan is formulated. 
 
2.6 The Bullwhip Effect 
 
All elements of the supply chain are interconnected and interdependent. It is the 
role of the SCM to ensure that each link in the chain is integrated, cohesive and 
working towards shared goals and objectives, whilst remaining lean, respon-
sive, innovative and profitable. Predictability and minimal disruption are im-
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portant elements of a competitive, efficient and well working supply chain.  It is 
therefore essential that all of those engaged in a supply chain are collaborating, 
sharing information and acting in coordination with one another. Inefficiencies or 
breakdowns in these areas at any stage of the supply chain can have a dis-
torting effect on what is delivered to the final customer, and can lead to lower 
profitability throughout the supply chain, and what is commonly known as the 
“bullwhip effect.” (Sander 2012, p.8.) 
 
It has been witnessed that the distortion and fluctuation of information increases 
as it progresses up the supply chain from retailers, manufacturers to suppliers. 
This is what is referred to as the “bullwhip effect” as inaccurate and distorted 
information moves up the chain like a bullwhip uncoiling. In response to this, 
each stage in the chain progressively carries more stock to compensate for the 
lack of information. (Sander 2012, p.8.) The longer the supply chain becomes, 
the more likely the bull whip effect will occur, as manufacturers and suppliers 
are further away from the final customer, and breakdown in sharing information 
between links in the chain is more likely; this is particularly the case for compa-
nies operating at a global level. The results of the bullwhip effect are excessive 
inventory quantities, poor customer service, cash flow problems, stock outs and 
high material costs, overtime expenses and transport costs. (Lysons & Farring-
ton 2006, p. 334.) 
 
To avoid and resolve the bullwhip problem, it is important to ensure transparen-
cy and information sharing throughout the supply chain. The importance of in-
formation sharing and the management of such fluctuation have seen the onset 
of Enterprise Resource Planning (ERP) and SCM systems and software, which 
support internal and external integration and exchange of real time information, 
such as finance, manufacturing and distribution, at each level of a supply chain. 
(Simichi-Levi et al 2003, p. 272.) 
 
2.7 Future SCM Trends 
 
As modern supply and value chains continue to develop as a result of rapidly 
evolving global and technological environments. A number of trends are emerg-
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ing that are impacting the way supply chains are designed and managed, and 
are creating unique challenges for businesses. According to Nada Sanders and 
Sumantra Sengupta the top trends that are emerging include: 
1. Increased globalisation and the spread of the global marketplace. Changes 
in information technology, transportation and government policies have 
meant that there is no avoiding the global economy. Whilst this has brought 
numerous advantages for companies and the consumer alike, such as a 
larger choice of product sources for companies; and more choice, higher 
quality and lower prices for the consumer. It has also created a number of 
challenges such as the distance barrier when shipping products over vast 
distances. 
 
2. Increased outsourcing, including the hiring of third and fourth parties to un-
dertake activities that were traditionally the sole responsibility of the manu-
facturer. 
 
3. Lean supply chains, whereby companies in the supply chain that are directly 
linked by upstream and downstream flows will be required to work in coordi-
nation and cooperation with one another to reduce waste and cost. 
 
4. Supply chain security and maintaining product integrity as goods are moved 
around the world and across multiple national borders. Modern stringent se-
curity requirements have resulted in more complex supply chains, and the 
ability to protect security while being efficient is a key issue. Other key is-
sues in this area include increased risk of theft and product tampering. This 
is a particular issue in the area of pharmaceutical. Modern security methods 
include the use of electronic seals to prevent tampering, to using RFID and 
GPS technologies to track product movement. 
 
5. Service chains will become more important than product chains. As con-
sumer power grows and demands increase from pre- and post-sale, compa-
nies increasingly have to develop ways to effectively couple and manage ac-
tivities in these areas. An important element in this will be a company’s abil-
ity to listen to and react to customer feedback. 
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6. Companies will have to fully report their supply chain externalities in an open 
and transparent manner, including their approach to sustainability and cor-
porate social responsibility in the communities they operate. 
 
7. Supply chains will be designed to serve the base of the pyramid, meaning 
that companies will have to adapt their products and methods to target and 
tap the market potential the larger number of consumers with low incomes. 
This will necessitate companies having to alter their traditional mind-set of a 
“cost-plus” model to a “not to exceed” cost model. 
 
8. Product clock speeds/life cycles will determine the number and type of sup-
ply chains, with “fast clock speed” becoming more the norm than the excep-
tion. This has had the knock on effect that companies can no longer employ 
a single supply chain approach, and must have distinct product supply 
chains to meet each product’s needs. 
 
9. Technology to support SCM, such Enterprise Resource Planning (ERP) and 
the concept as Software as a Service (SaaS); will primarily be on tap, with 
users paying for the ability to use the capability rather than have to invest in 
costly fixed systems and their ongoing associated costs. 
 
10. Artificial intelligence will be embedded in the mainstream supply chain activi-
ties, which allow systems to access algorithms that learn and retain past 
knowledge and experience, and thereby automatically update and improve 
(Sanders 2012, p. 20-25; Sengupta 2013.) 
 
It is evident from these examples that the supply chain and value chain envi-
ronment is changing rapidly, and will continue to do so in the future. It is there-
fore essential for any company no matter of their size or business type to con-
tinuously review and develop flexible SCM systems in order for them to adapt 
quickly and remain competitive, whilst delivering value to their end customer or 
user.  
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3 Sustainable SCM 
 
One of the biggest trends and factors effecting the design and management of 
supply chains is “Sustainable” business practices, which is of increasing im-
portance to global governments, non-governmental and activist organisations 
and consumers; who are demanding, through means such as legislation and 
changes in buying habits, that companies operate in an ethical and appropriate 
manner. The Merriam Webster Dictionary (2015) defines “Sustainable” as being 
 
“Able to be used without being completely used up or destroyed, involving 
methods that do not completely use up or destroy natural resources and being 
able to last or continue for a long time.” 
 
Figure 3 provides a high level overview of the three core spheres of sustainabil-
ity, which are considered to be the key elements that enable companies and 
other societal players to develop process or management systems that contrib-
ute to the development of vibrant national and global economies, in addition to 
the raising of the quality of life in which they operate whilst respecting the need 
to sustain natural resources and protect the environment. (Vanderbilt University 
2015.) 
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Figure 3. the Three Spheres of Sustainability (Vanderbilt University 2015) 
 
Companies primarily exist to make money and a return on investment for their 
owners and stakeholders, but now they are increasingly expected to be "social 
responsible," and SCM's play a key role in this through effective, efficient pur-
chasing and manufacturing. Through social responsible and sustainable busi-
ness practices companies are producing better products, using fewer re-
sources, appealing to a larger consumer audience and avoiding environmental 
regulations. At the same time such companies are able to stay ahead of com-
petitors by forcing governments that enact competitors to develop similar re-
sults, invest in technology or pay heavy fines. However, it takes a committed 
organisation to develop a truly integrated and socially responsible supply chain 
and motivate suppliers to do the same.  
 
Sustainable SCM 
 
Most people do not think about how or where the products they purchase or 
use, were sourced from and produced. However, supply chains can have a sig-
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nificant environment and social consequences, including environmental costs, 
health and human safety risks, and the cost of waste. Over recent decades the 
combination of heightened customer awareness and demand for ethically man-
ufactured products and an increase in regulatory standards; companies now 
have to be more accountable for the impact that their actions and products and 
services, and the associated supply chains are having on the environment and 
the societies in which they are being performed. Focus on “green” and sustain-
ability, and issues such as the environment and social responsibility; have 
therefore become key elements of SCM. 
 
Essentially companies are there to make money, but now they are increasingly 
expected to be "social responsible," and SCM play a key role in this through 
effective, efficient purchasing and manufacturing. Through social responsible 
and sustainable business practices companies are producing better products, 
using fewer resources, appealing to a larger consumer audience and avoiding 
environmental regulations. At the same time such companies are able to stay 
ahead of competitors by forcing governments that enact competitors to develop 
similar results, invest in technology or pay heavy fines. 
 
In addition there are four documented types of payoff that result from a compa-
ny improving its sustainable performance. These are: 
 
 Financial Payoffs – these include reduced operating costs, increased reve-
nue, lower administrative costs, lower capital costs, and stock market premi-
ums. 
 Customer Related Payoffs – these include increased customer satisfaction, 
product innovation, improved reputation, increased market share and new 
market opportunities. 
 Operational Payoffs – these include process innovation, productivity gains, 
reduced cycle times and waste minimisation. 
 Organisational Payoffs – these include employee satisfaction, improved 
stakeholder relationships, reduced regulatory intervention, reduced risk and 
increased organisational learning (Sanders, N 2012, pp. 377.) 
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However, it takes a committed organisation to develop a truly integrated and 
socially responsible supply chain and motivate suppliers to do the same.  
 
4 Supply and Value Chains and SCM in the Pharmaceutical 
Industry 
 
The pharmaceutical industry includes activities such as the manufacture, devel-
opment, marketing and distribution of drug products including quality assurance 
of these activities (University of Helsinki, 2006). In 2014, the global pharmaceu-
ticals market was worth US$300 billion a year, a figure expected to rise to 
US$400 billion in the next three years. The ten largest drugs companies control 
over one third of this market, several with sales of more than US$10 billion a 
year and profit margins of about 30%. Six companies are based in the United 
States and four in Europe. It is predicted that North and South America, Europe 
and Japan will continue to account for a full 85% of the global pharmaceuticals 
market well into the 21st century. (The World Health Organisation, 2014.) 
 
Traditionally, the majority of the largest pharmaceutical companies operated 
using a simple supply chain model consisting of suppliers of raw materi-
als/chemicals, pharmaceutical companies, wholesalers, retailers, in some plac-
es insurers and ultimately the final end-user. In most instances there was mini-
mal communication between each party and there was no real desire to pursue 
efficiency gains. Regulatory constraints restricting the activities of smaller rival 
companies and favourable tax structures in a limited number of locations 
worked in the industry’s favour. In addition, to steady profits from customers 
dependent on a limited number of companies’ products made change undesira-
ble or at least unnecessary. (Ehrhardt, Hutchens & Higgins, 2012.)  
 
However recent developments and disruptions in the traditional operating envi-
ronment, most notably the emergence and increasing influence of cheaper ge-
neric drug manufacturers, as well as changes in customer demand patterns, 
new and more agile and innovative rivals and increasingly restrictive global reg-
ulatory environment, have meant that traditional pharmaceutical companies 
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have had to change their game plan, to stay ahead of the field, remain profitable 
and deliver quality products that the customer wants. 
 
4.1 The European Pharmaceutical Industry 
 
The presence of a viable, well-functioning and effectively regulated pharmaceu-
tical industry is a major contributing factor in the betterment of the health and 
the quality of life of not only citizens of the European Union, but also in other 
countries and particularly those in the developing world; through the develop-
ment and supply of remedies to an increasing number of patients, through a 
more timely, widespread and equal access to pharmaceuticals. It also acts as a 
catalyst to medical progress through researching, developing and bringing new 
medicines that improve health and quality of life for patients around the world.  
 
In addition to delivering value to patients the pharmaceutical industry is also a 
key asset of the European economy, and the European Commission view it as 
one of Europe’s top performing business sectors and a key driver of economic 
growth in a period of increased operational difficulties for most of the EU’s busi-
ness sectors. In 2013 Pharmaceutical Companies invested an estimated € 
30,630 million in R&D in Europe, and directly employed more than 690,000 
people and generated three to four times more employment indirectly – up-
stream and downstream – than it does directly. (European Federation of Phar-
maceutical Industries and Associations 2014.)  
 
It also provides a major source of growth and economic performance as reflect-
ed by its average annual growth rate. The production index increase amounts to 
2.5% (between 2006-2011) and the growth in labour productivity per person 
employed is 3.6% over the same period. The European pharmaceutical industry 
serves as a major contributor to the EU’s trading power. The EU is also one of 
the world’s major traders in medicinal and pharmaceutical products. In 2013, its 
total trade amounted to € 156.9 billion (taking into account all 28 EU Member 
States) and the value of exports reached more than € 107.4 billion. Therefore a 
viable European pharmaceutical industry is important for European public 
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health, economic growth, trade and science. (European Commission 2014, p.3-
4 & European Federation of Pharmaceutical Industries and Associations 2014.) 
 
4.2 Major Drivers and Challenges Facing the Industry 
However, the sector faces real challenges. As well as increasingly burdensome 
regulatory hurdles and escalating R&D costs, the sector has been severely hit 
by the impact of fiscal austerity measures introduced by governments across 
much of Europe since 2010 (European Federation of Pharmaceutical Industries 
and Associations 2014). In order to get an understanding of how effective and 
efficient SCM can be used to increase economic performance and deliver value 
both to EU pharmaceutical companies and their customers, it is important to 
have an overview of these challenges going forward and their key influences. 
The following list provides details of some of these issues according to the Eu-
ropean Commission and the European Federation of Pharmaceutical Industries 
and Associations (EFPIA): 
 
1. Demographic Change - One of the key challenges facing the EU is Demo-
graphic change. Over the next 50 years, the number of EU residents aged 
65 and over is expected to increase dramatically from 92 million in 2013 to 
148 million in 2060. As health-related spending generally increases with the 
age of a person and the prevalence of chronic diseases like diabetes or de-
mentia will rise with an ageing population, consequently such demographic 
transition is viewed as a major challenge for the financial sustainability of EU 
health and care systems. Public spending on health  care already accounts 
for more than 7% of GDP in the EU, this is expected to increased significant-
ly by 2060 public when expenditure on acute health care and long-term care 
measured as a percentage of GDP is expected to increase to between 8.5 
and 9.1% of GDP. 
 
2. Resistance to Existing Diseases and the Emergence of New Threats - A 
higher degree of urbanisation, migration of people from other EU and non-
member states, particularly from the developing world; better mobility in-
crease the risk of epidemics of existing and new diseases, including those 
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that had previously been eradicated in the EU, and increasing resistance of 
diseases to existing medicines; have all contributed to new challenges for 
Pharmaceutical Industry. Additionally, changing life styles are expected to 
be a further driver in defining public health needs. Chronic diseases like cor-
onary heart disease and diabetes are becoming more widespread and in-
creasingly affect not only the older part of the population. 
 
3. Investment in Pharmaceutical Research and Development - Developing 
medicinal products is increasingly complex, expensive and risky. Conse-
quently, R&D expenditures in the pharmaceutical sector have grown dramat-
ically, which has resulted in a widely acknowledged decline in Pharmaceuti-
cal R&D productivity largely due to the increased costs associated with de-
veloping a new medicine. R&D costs in the pharmaceutical industry are es-
timated to amount to approximately € 1 billion for each new medicinal prod-
uct entering the market, while in 1975 development costs amounted only to 
€ 149 million (in 2000 prices). An increasing focus on more complex diseas-
es has also led to increasing R&D costs and R&D projects targeting diseas-
es have a lower average probability of successful development. Another 
reason relates to regulatory a factor which has led to higher demands by 
marketing authorisation agencies with regard to the quality, scope and scale 
of data submitted as a consequence of legitimate public health objectives. 
 
4. Policy Consistency regarding the Pharmaceutical Sector - The rules 
affecting pharmaceuticals is set at both EU and national level. The frame-
work concerning the placing of a pharmaceutical product on the market in 
the EU and other related subject matters (e.g. the supervision of products af-
ter authorisation, the manufacturing, wholesaling or advertising of medicinal 
products for human use, clinical trials, and specific rules addressing the par-
ticularities of certain types of medicinal products and promoting research in 
areas like orphan medicinal products) fall under the competences of the EU. 
This combination of EU and national standards and regulations can often 
lead to confusion and extra cost for the Pharmaceutical Industry. 
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5. Ethical Behaviour - Public awareness and demands, with regard to the so-
cial and ethical performance of enterprises is increasing and the sector has 
to respond to this challenge. Consumers are increasingly expecting the in-
dustry to go beyond a purely economic role and make a growing contribution 
to society as a whole, particularly in times of crisis. This increased interest of 
the public in the ethical conduct by all parties concerned, i.e. industry, 
healthcare professions, the distribution chain, hospitals, and public authori-
ties, has also been reflected in the Commission’s activities and demands on 
the industry in terms of performance and reporting. Consequently the phar-
maceutical industry is subject to increased public scrutiny since a major part 
of its revenues is paid by public bodies, particularly in European welfare 
states. This issue and is role in delivering value to both the industry and the 
consumer is covered in more detail in Section 4.2 of this report.  
 
6. Increased Competition from Emerging Economies - There is rapid 
growth in the market and research environment, as well as a proliferation of 
generic medicines; in emerging economies such as Brazil, China and India. 
This has resulted in a gradual migration of economic and research activities 
from Europe to these fast-growing markets where lower research and devel-
opment costs and a less stringent regulation environment, allow for a better 
return on investment. The IMS Retail Drug Monitor reported in 2013 that the 
Brazilian and Chinese markets grew by 17% and 14% respectively com-
pared to an average market growth of 1% for the five major European mar-
kets and 3% for the US market (European Commission 2014, p.3-13 & Eu-
ropean Federation of Pharmaceutical Industries and Associations 2014.) 
 
4.3 Role of SCM in Delivering Value and Profitability 
 
Prior to the 1990’s, the Pharmaceutical Industry supply chain and its subse-
quent SCM focussed on the sourcing and manufacture of test materials to be 
used in clinical trials of medicine and related products, for regulatory scrutiny. 
The justification for this was that manufacturers believed that there was little 
value in investing any more than necessary in a medicines supply chain before 
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they were granted approval. This approach resulted in a narrow and short-term 
mind-set leading to: 
 
 A lack of focus on the performance of suppliers and their supply chain, 
when making decisions on procurement policies and practices 
 Short-term tactical sourcing and outsourcing of decision making 
 Carrying of large holding inventories to counter any lost sales 
 Employing strategies of maximising batch sizes to minimise cost per unit 
 Extensive off-line testing and checking of documentation 
 A resistance to change  
 
By focussing its supply chain primarily on cost and regulatory, the Pharmaceuti-
cal Industry failed to connect with its end consumer and tended to adopt a take 
it or leave it approach, and thereby failed to deliver value. (Rees 2011, p. 16.) 
 
4.4 Modern Pharmaceutical Industry Supply Chains and SCM 
 
Since the 1990’s, major economic and operating changes and disruptions cou-
pled with a more sophisticated consumer, has forced Pharmaceutical Compa-
nies to review and amend their approach to SCM and Value delivery, in order to 
remain competitive and fend off competition from emerging economies. The 
basic concept of interconnectedness still exists however SCM has become in-
creasingly complex with the realisation those quick fixes are no longer a viable 
approach to long-term profitability and that the identification of root-cause is-
sues and sustainable solutions is the way forward. (Rees 2011, p. 18). 
 
The primary objective of Pharmaceutical Companies as well as Governmental 
and public sector pharmaceutical supply chains is to provide access to easy 
and on time access to medicines and associated supplies, promote the proper 
use of the medicines, and to ensure quality, safety and efficacy of these medi-
cines. Whilst this can result in highly complex which vary according to national, 
and in the case of the European based companies Union legislations and mar-
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ket structures; a general supply chain process exists, which can be attributed to 
every pharmaceutical company and is demonstrated in Figure 4. 
 
 
 
Figure 4. Pharmaceutical supply chain (PricewaterhouseCoopers 2011) 
 
As has previously been highlighted, outsourcing is of growing importance to the 
European pharmaceutical industry, with Phoneix Group (one of the three large 
pan-European pharmaceutical companies) stating that “Today there is not a 
single country in Europe where it is not in manufacturers’ interests to outsource 
their entire distribution and logistics requirements, whether for drugs, medical 
products or veterinary pharmaceuticals, to a specialist company operating with-
in an efficient logistical system. This logistical partner takes over responsibility 
for distribution to all wholesalers (Cmolik 2012, p.18-19.)” 
 
Increasingly modern pharmaceutical companies are outsourcing an increasing 
amount of their everyday activities to 3rd and 4th party service providers, and 
wholesalers. Typically a pharmaceutical company will manage its own supply 
chain activities such as planning, operational procurement and delivery func-
tions regionally, and their enabling, manufacturing and assembly and strategic 
procurement functions globally. They outsource about 6% of their planning and 
sourcing activities; 25% of their new product development activities; and 20%-
40% of their delivery activities. The most important value drivers for these com-
panies are maximum delivery performance (100%), minimised costs (94%), 
maximum volume flexibility and responsiveness (78%) and minimised risks 
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(78%). An issue of increasing importance and focus for the leading companies 
is collaboration with key customers and suppliers and end-to-end supply chain 
planning. A great weight also continues to be placed weight on continuous im-
provements in manufacturing and its associated activities. (PriceWaterHouse 
2013, p. 26.) 
 
Additionally these wholesalers, as well as 3rd and 4th Party Service Providers; 
offers services such as professional storage and transportation in accordance to 
the necessary legislation and special requirement for drugs handling, as well as 
other tailor-made solutions required by the Pharmaceutical Industry. These tai-
lor-made solutions include such things as product tracking, monitoring of tem-
perature, humidity and exposure to light, and country specific packaging and 
labelling. (Cmolik 2012, p. 19.) 
 
4.5 Development of a Pharmaceutical Product and typical Supply Chain 
 
The development and bringing to market of new drugs is of ever increasing 
costs and reduced margins. Efficient supply chains and SCM provide an oppor-
tunity for EU pharmaceutical companies to increase their return on investment. 
A typical drug development supply chain can be broken-down into five stages, 
these being (i) preclinical development, (ii) preparing for phase 1 of clinical trial 
i.e. is the drug safe for human use? (iii) phase 2 and proof of concept, (4) phase 
3 registration-orientated and pivotal clinical trials, and (v) commercial launch 
and supply and Phase 4 clinical trials after launch. These stages are typically 
referred to as “Commercial” and “Clinical” supply chains, each of which has its 
own characteristics and a drug development can be dropped at any stage with-
out recouping any of the outlay that has been made. Therefore SCM is critical in 
developing products that come to market and produce a return on investment, 
and minimise costs for products that are dropped. Table 1 provides a summary 
of the main differences between “Commercial” and “Clinical” supply chains and 
their Value-Chain parameters (Rees 2011, p105-110.) 
 
Value-Chain Parame- Clinical Value-Chain Commercial Value-
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ter Chain 
Inventory Expensed Balance Sheet Asset 
Demand/capacity Determinate (set by 
clinical protocols) 
Uncertain (driven by pa-
tient markets) 
Working capital Low High 
Agreements Investigator, Contract 
Research Organisa-
tions, development, 
quality/technical 
Licensing, distribution, 
quality/technical, and 
commercial supply 
Compliance Increasing Current 
Good X Practice (X can 
mean: Clinical, Labora-
tory, Manufacturing, 
Pharmaceutical,) ap-
plies 
Validation, change con-
trol, traceability, preap-
proval inspections 
Insurance Limited Product liability, marine 
insurance, etc. 
Supply base calibre Support needs of spe-
cific studies 
Able to cope with long-
term market supply 
Cost of Goods High: immature pro-
cesses and low volume 
Need to manage cost 
reduction to leverage 
higher volumes/process 
maturity 
Distribution logistics Mainly express couriers 
to sites 
Complex channel net-
works to wholesalers, 
clinics, hospitals and 
pharmacies 
International move-
ments 
Shipped as research 
materials 
Liable to stringent as-
sessment because of 
implications for duty, tax, 
etc. 
Packaging Mainly regulatory driv-
en, simple design and 
Many stakeholders for 
approval and complex 
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origination reprographics/origination 
 
Table 1. Main differences between “Commercial” and “Clinical” supply chains 
and their Value-Chain parameters (Rees 2011, p105-110) 
 
This table demonstrates how difficult it can be for a pharmaceutical company to 
develop and bring a product to market, and how critical effective SCM is in pro-
ducing value for both the company and the consumer. 
 
4.6 Understanding the Pharmaceutical Industry Value Chain 
 
As the cost of developing and bringing new products to market and regulatory 
burdens have increased the landscape of the European pharmaceutical industry 
has altered dramatically. The focus of the industry has moved from quick fixes 
and cash cows to become increasingly on understanding the effects of disease 
and infections at a molecular level in an attempt to develop better and more 
specifically targeted innovative products, which reduce the risk of product de-
velopment failure and subsequent monetary and value for the company, and to 
deliver better products to the consumer. 
 
Elements of the pharmaceutical value chain typically focus on the consum-
er/patients receiving the correct medicine, at the appropriate time and from a 
convenient location. Ensuring that these three core elements are achieved re-
quires a complex value chain which includes the manufacturing of the medicine, 
distribution to the dispensing point and dispensing to the end-user. An initiative 
between the World Health Organisation (WHO) and Health Action International 
(HAI), has established a 6 key-stage methodology for classifying the level of 
medicine build up at each stage of the supply and value chain these being (i) 
the manufacturer selling price, (ii) cost, insurance, freight charges (CIF), import 
tariffs and charges, (iii) importer margin, (iv) distribution margins, (v) retailer 
margin, and (vi) taxes. The combination of the value added at each stage as 
well as their linked costs, provides a basis for understanding the pharmaceutical 
supply and value chains. The degree to which these occur depends on the so-
phistication and efficiency of these Chains and common commercial practices.  
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Table 2 provides a breakdown of the pharmaceutical/drug industry value chain 
by stakeholder (IMS Institute for Healthcare Informatics 2014, p.1-3) 
 
Illustrative Manufacturer of drug Distribution Dispensing 
Cost Incurred  R&D 
 Manufacturing 
Costs 
 Import duties & 
taxes 
 Promotion & edu-
cation 
 Medicine acquisi-
tion 
 Handling & deliv-
ery 
 Obsolescence 
costs 
 Capital costs 
 Promotion & edu-
cation 
 Medicine acquisi-
tion 
 Labour facilities, 
equipment 
 Medicine wast-
age 
 Capital costs 
 Education 
Value Added  Innovation 
 Regulatory docu-
mentation 
 Quality assured 
manufacturing 
 Education 
 Ensuring continu-
ous medicine sup-
ply 
 Waste manage-
ment 
 Order processing 
 Education 
 Medicine availa-
bility 
 Pharmacist ad-
vice 
 Patient conven-
ience 
 Additional 
healthcare ser-
vices 
 Education 
 
Below the value added by each illustrative is examined in more detail: 
 
 Value added by the manufacturer relates to new generation medicines and 
relates to the treatment of the consumer/patient. Advances may include 
tackling a new disease, improving health outcomes, treatment safety, reduc-
ing side-effects and ability to treat specific ailments and patient de-
mographics. In addition, there are potential wider benefits to health systems 
including reducing the burden on health systems and overall benefits to so-
ciety. Whilst the main cost in drug discovery and development is R&D, the 
value-added extends beyond the drug produced and includes advancements 
in scientific knowledge and technological advancements, which have the po-
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tential to diffuse into other areas of industry. Additionally, promotional and 
educational efforts by the manufacturer can help those working directly with 
consumers to ensure the most appropriate, effective and quality standard of 
care. (IMS Institute for Healthcare Informatics 2014, p.7.) 
 
 The key value added by distributors is the function to resolve the challenge 
of being able to meet the various needs of the consumer, through supplying 
the manufacturers’ medicines, without requiring the retailer to carry large in-
ventory levels. Another role of the distributor is to provide the required work-
ing capital for pharmacists to allow them to purchase the end products, be-
fore receiving payment from the end-user.  Finally, wholesalers are also able 
to provide a wide variety of commercial support functions to independent 
pharmacists to improve their business, including sales training and educa-
tion programmes for pharmacists. (IMS Institute for Healthcare Informatics 
2014, p. 10.) 
 
 A role of the retail pharmacist is that of logistics and being able to provide 
the correct drug, in the right quantity, at the right time and place. In addition, 
the pharmacist may also be required to correct prescription errors, pro-
cessing prescriptions, labelling, etc. As well as advising consumers on prod-
uct safety and possible side effects. Another recent phenomenon has been 
drug shortages. Although the EU can be considered as one of the most effi-
cient producers and market for pharmaceutical products, countries such as 
the Netherlands has indicated a 3-5% unavailability of products at the time 
of order. Such shortages can result in adverse health outcomes and con-
sumers switching products. Consequently pharmacists dedicate a large 
amount of their time sourcing drugs or finding alternatives. Finally, in recent 
years the role of the pharmacist has moved beyond the traditional role of 
dispensing drugs, but to advising on patient health related issues such as 
disease management, and nutrition and lifestyle factors. (IMS Institute for 
Healthcare Informatics 2014, p.14.) 
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5 Sustainable Pharmaceutical Supply and Value Chains in the 
EU 
 
The pharmaceutical industry contributes many benefits to Europe and its citi-
zens: 
 Better quality healthcare and treatment choices; 
 Value solutions that meet national healthcare and social security budgets; 
 Investment in innovation in Europe, bringing highly skilled employment 
and contributing economic benefits. 
 
Sustainable, integrated and collaborative business practices is of increasing 
importance in the development of a sustainable pharmaceutical industry within 
the EU, and many companies are coming together to work together on issues 
that will benefit the whole industry, as well as the customers it serves and the 
communities in which they operate. In the EU this has led to the establishment 
of the European Federation of Pharmaceutical Industries and Associations 
(EFPIA), who represents the pharmaceutical industry operating in Europe. It 
acts as a single voice on the EU scene of 1,900 companies, including some of 
the largest global companies such as GlaxoSmithKline (GSK), Pfizer and 
Roche; by fully engaging with the EU and, in the discussions on the formulation, 
revision and implementation of regulation and EU legislation. (EFPIA, 2015.)(1.) 
The EFPIA along with the European Generic Medicines Association (EGA) have 
identified three priority action points which they believe if implemented success-
fully will help build a healthier EU pharmaceutical and health industry, which 
benefits both the manufacturer and end-user. These priority areas are: 
 
 Recognising that medicines are essential to improve patient outcomes and 
equity of access to healthcare across Europe; 
 Supporting a more sustainable and predictable business environment to in-
centivise the pharmaceutical industry to invest in bringing better and more 
cost effective treatments to patients; 
 Fostering an environment that will make the EU an attractive global hub for 
pharmaceutical research and manufacturing. 
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EFPIA is active in partnering in EU Research programmes, such as the IMI (In-
novative Medicines Initiative), Europe’s largest public-private partnerships. They 
also work on corporate social responsibility initiatives with others healthcare 
stakeholders, including patient groups and healthcare professionals (European 
Federation of Pharmaceutical Industries 2015.) (2.) 
 
In addition to collaborative approaches to developing sustainable supply and 
value chains, pharmaceutical companies are increasingly recognising the im-
portance of ensuring a reliable supply of drugs and other medical products, and 
as a result are no longer considering each action in the supply chain in isolation, 
and are employing systems that centralise and coordinate the entire supply 
chain activities, from raw material procurement to manufacturing to product 
shipment. In this way companies are able to operate in a more economic and 
sustainable ways which enable them to steadily reduce costs, increase their 
flexibility and delivery reliability, and maintain high standards of quality, safety 
and environmental protection on a global basis. It also enables them to meet 
increasingly stringent legislative and quality requirements such as completing 
regularly audits by internal experts, regulatory authorities and external consult-
ants. (Bayer Healthcare 2015.) These sustainable practices are analysed in 
more detail in Section 6 of this report. 
 
6 Empirical Research 
 
The objective of the study was to examine how important SCM is in the Euro-
pean Pharmaceutical industry as a means for developing and delivering effec-
tive and sustainable supply chains and value chains. In addition, it also had the 
objective of identifying future trends and threats to the industry, and how SCM 
can be used to address these. Respondents were asked to give a brief over-
view of their current supply chain networks and SCM, and were then given an 
opportunity to provide their views and opinions on the key objectives that have 
been described in Section 1.2 of this report. Additionally, respondents were giv-
en an opportunity to provide any additional comments that they wished to make 
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on how more effective and sustainable SCM in the pharmaceutical industry can 
be achieved, which were not directly addressed in the questions posed to them. 
 
6.1 Data Collection  
 
The data was collected using two structured questionnaires. One was sent to 20 
European based pharmaceutical companies and another to 7 European nation-
al trade associations representing pharmaceutical companies in different Euro-
pean countries. The names of these Companies and Trade Associations, was 
obtained from EFPIA website and they represent all of the major large Europe-
an pharmaceutical companies. The questionnaires were based on the same 
questions, but the questionnaire sent to pharmaceutical companies contained 
additional questions on the nature of the supply chains and SCM they used, and 
were therefore not relevant to the Trade Associations. Copies of the question-
naires can be found at Appendix A and B of this report. 
 
A structured questionnaire was chosen as it enables a researcher to gather and 
analysis the opinions of a targeted group of contacts on a specific subject in a 
structured way, enabling them to produce hard facts and statistics on a number 
of predetermined questions on issues that had come to their attention, through 
their theoretical research. In each questionnaire the respondent receives exact-
ly the same set of questions, in the same order. The researcher chose this form 
of empirical data collection as it enabled them to seek the views of a specific 
group of people located in a number of different European locations, which 
would have been difficult in terms of practicality (time and money) if other forms 
of data collection such as face to face interviews or telephone interviews had 
been used. 
 
The questionnaires were created with the Google Forms system and a personal 
link to the questionnaire was sent through email to individuals responsible for 
SCM and corporate media handling. Google Forms saved all the answers and 
the received data was processed on Google Forms. This data was supplement-
ed with additional information that had been gathered in prior surveys relevant 
to the objective of the study. 
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6.2 Background to Respondents 
 
The response rate to the empirical evidence gathering was very low with only 
one positive response to the questionnaire. In most cases the researcher re-
ceived no response, or was informed that a response was not possible due the 
large number of requests that are received by companies on such issues. 
Therefore, the researcher has used the one response that he received as a 
case company and used previous empirical evidence that has been gathered on 
similar issues to back up their findings. Due to confidentiality issues the case 
company shall be referred to as Company X. 
 
Company X Case Study 
 
Case Company X provides a good representation of the target market that the 
researcher attempted to survey. It is a very large multi-national company locat-
ed in the United Kingdom, and it is active in Asia, Africa, North America, South 
America, Oceania and other European Countries (Non-EU Members). They 
employ approximately 130,000 people directly, over 5000 of who are employed 
directly on supply chain related issues. Additionally it has a specialised supply 
chain management team located within its central headquarters, which is typical 
of most large multi-national Pharmaceutical Companies. Company X’s supply 
chain network is made up of over 5000 partners/suppliers, and 25 to 50% of its 
SCM functions, including documentation handling and processing and freight 
booking; is outsourced to 3rd or 4th Party Service Providers who are required to 
commit to and apply Company X’s supply chain objectives. 
 
In section 4.3 of this report, the researcher describes a simplified version of a 
pharmaceutical company supply chain. As part of the questionnaire the re-
searcher asked responders to briefly describe a typical supply chain in their 
company. Company X’s typical supply chain is: 
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Figure 5. Company X typical Supply Chain 
 
This description supports the theoretical evidence the researcher undertook, it 
also shows that pharmaceutical companies supply chains are now relatively 
short, and are moving towards supplying the end user (customer) directly rather 
than through wholesalers, which had often been the case in the past. By doing 
this Pharmaceutical Companies are able to obtain value/profits which had pre-
viously been lost at this stage in the chain. It also enables them to be in a better 
position to respond quickly to the end users demands and needs, and reduce 
wastage in the supply chain. 
 
In section 4.1.2 the researcher examines some of the major drivers and chal-
lenges facing the European pharmaceutical industry, from the empirical evi-
dence it was discovered that the biggest drivers and challenges facing Compa-
ny X are worldwide drugs legislation, chemicals, animal by-products and medi-
cine licensing. In addition they are also challenged by the multiple pieces of dif-
fering legislation in place in different countries; worldwide shipping and tem-
perature controlled shipping are also an issue. 
 
The major focus of this research paper was to examine how effective and sus-
tainable SCM in Pharmaceutical Industry can be used to develop future compet-
itiveness for traditional Pharmaceutical Companies. However, whilst sustainabil-
ity is very important to Company X, they were unsure whether as to how this 
could be achieved within the current environment the Industry is operating in. 
That said Company X stated when asked to describe briefly how they thought 
sustainable and responsible agendas could be be used as a tool for competi-
tiveness and better SCM, they felt that this could be achieved by embedding 
sustainability into their procurement and supply chain, and stopping being part 
of the problem through their purchasing behaviour. They stated that without a 
External Supply 
of raw 
materials 
Company X 
Manufacturer 
3rd Party 
Freight Control 
Tower 
3rd Party 
Distributor (i.e. 
Pharmacist) 
End-User 
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unified message to suppliers over social and environmental practices they will 
not change. Turning hidden cost and risk into competitive advantage through 
supply base collaboration is of strategic importance, and an individual company 
cannot change an entire culture and infrastructure of an industry. In order to 
induce systemic change Pharmaceutical Companies and their partners need to 
overcome distrust and coalesce with peer companies in areas of mutual inter-
est. 
 
Company X consider the most important payoffs of a more sustainable supply 
chain are Customer Related Payoffs, including increased customer satisfaction, 
product innovation, and improved reputation; and the major drivers and chal-
lenges facing the European Pharmaceutical Industry in the future are customer 
demographic change, policy consistency regarding the Pharmaceutical Sector 
and ethical behaviour. 
 
Finally Company X was given the opportunity to make any final comments on 
their supply chain. They stated that patients and consumers rely on them to 
provide an uninterrupted supply of medicines and products, manufactured to the 
highest-quality standards and spend over approximately €4 billion each year 
manufacturing and supplying products to help people do more, feel better and 
live longer. An effective and responsibly managed supply and distribution sys-
tem is essential for them to get high-quality products to the right places at the 
right time. If they do not do this, people’s health may suffer and their lives may 
even be at risk. To protect the interests of their patients and consumers, they 
aim to work with responsible suppliers who meet the same quality, social and 
environmental standards as themselves. 
 
Ethical conduct is a priority and they are committed to performance with integri-
ty. They have robust policies and compliance processes covering all their oper-
ations, including the way they reward their sales representatives, how they mar-
ket their medicines and vaccines, and how they work with stakeholders. Their 
compliance programmes embed the same standards across their business units 
in different countries. These include a Code of Conduct, which outlines how all 
employees should apply our Values and Behaviours, and a Global Code of 
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Practice for Promotion and Customer Interactions, which applies to all employ-
ees involved in sales and marketing as well as third parties acting on their be-
half. All employees have access to whistleblowing mechanisms that they can 
use to get advice and to report suspected cases of misconduct – anonymously 
if required. 
 
6.3 Supporting Empirical Evidence 
 
In order to support the reliability and consistency of this empirical evidence, the 
researcher has chosen to compare the response of Company X to similarly 
themed researchers that have been undertaken on the pharmaceutical compa-
nies by well-regarded and globally recognised industrial consultancy firms. 
 
In a survey of the pharmaceutical industry in 2013, PricewaterhouseCoopers 
(PwC), which surveyed over 500 supply chain executives, including those in-
volved in the Pharmaceutical industry, on the future trends in supply chains and 
SCM; discovered that the majority of pharmaceutical companies manage the 
planning, operational procurement and delivery functions of their supply chains 
regionally, and their enabling, manufacturing and assembly and strategic pro-
curement functions globally. Approximately 6% of planning and sourcing activi-
ties; a relatively high 25% of new product development activities; and between 
20%-40% of deliver functions are outsourced. In terms of supply chain perfor-
mance the leading pharmaceutical companies on average achieve Earnings 
Before Interest and Tax (EBIT) margins of 16.9%; Inventory Turnovers of 16,3 
and delivery performance of an impressive 97,4%. 
 
In the same survey PwC identified the leading value drivers for pharmaceutical 
companies. 100% of respondents identified “Maximum delivery performance,” 
which includes issues such as end-to-end supply chain planning and visibility, 
order fulfilment cycle-time reduction and improved manufacturing time and col-
laborative planning with key suppliers; as the most significant value driver. Oth-
er value drivers and supporting practices identified, included: 
 
40 
 Minimising costs (94%) – including decreased manufacturing costs 
through waste reduction and inventory reduction. 
 Maximum volume flexibility and responsiveness (78%) – including out-
sourcing to 3rd and 4th party suppliers, and partner involvement in decision 
processes. 
 Minimising risks (78%) – including short-term supply visibility through 
measures such as traceability; multiplying sources and reducing the reliance 
on single sourcing and regular review of suppliers. 
 Complexity Management (72%) – including the use of distributors and 
channel partners, differentiation of distribution strategies and development of 
multi-skilled employees who can handle a varied number of responsibilities. 
 Sustainability (67%) – including responsible supply chain partners foot-
prints and procurement and recycling returns through the supply chain. 
 Tax optimisation (53%) –import and export optimisation, intellectual proper-
ty and patent royalty optimisation and localisation of inventory ownership in 
tax efficient countries. (PriceWaterHouseCooper 2013, p. 26-27.)(1.) 
 
In a separate survey of Global Pharmaceutical Companies Chief Executive, 
PwC found that respondents believed that the biggest change factor and priority 
area for the sector are advancements in technology and that is essential for 
them to take advantage of the benefits that these bring, which they believe that 
they are doing through their strength in using innovation in their day to day 
business. Other significant issues affecting the sector are regulatory focus and 
business integrity; and the battle for talent, particularly with changing consum-
er/patient demographics and shifts in wealth with 72% of respondents believing 
this movement will have a significant transformational effect on their business. 
Innovation and intellectual property are also key priority areas and 38% of re-
spondents stated that they had completed or in the process of changing their 
R&D and innovation strategies to manage future business transformation 
(PriceWaterHouseCooper 2014, pp 4-5.)  
 
It was also discovered that the main restructuring activities that are planned by 
the industry are new strategic alliances or joint ventures, with the sector more 
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likely than other industries to seek alliances, joint ventures or outsourcing. 
However, the Pharmaceutical demonstrate less desire to do cross-border mer-
gers and acquisitions (PriceWaterHouseCooper 2014, pp. 15). 
 
7 Summary and discussion 
 
The main purpose of this research was to examine the importance of SCM in 
developing and delivering effective and sustainable supply chains and value 
chains in the pharmaceutical industry, by specifically examining the situation 
within traditional European based pharmaceutical companies. In addition, it was 
an objective to gain an understanding of the likely future trends and threats to 
the industry, and analyse how SCM can be used to address these. 
 
It is evident from this research that large multinational pharmaceutical compa-
nies, and not just those located within Europe; face a number of challenges  in 
managing and developing their supply chains, in order to unlock there “Value” 
and to maintain a sustainable business. However, this can be difficult for phar-
maceutical companies, particularly for large multinational companies who have 
complex supply chains and long product lead times. 
 
Unfortunately the results of the industry questionnaire were very low. However, 
the response that was received was from a well-known multinational pharma-
ceutical company that represented the company structure and size the re-
searcher was targeting. Therefore it provided a good representation of the 
pharmaceutical sector and the companies the researcher wanted to gain an 
understanding of, and the issues that Company X discussed would typically be 
the same for the other companies that the researcher contacted. The responses 
from Company X were also supplemented with results from similar surveys 
conducted by PwC on the pharmaceutical industry. 
 
From this research it has become apparent through both the theoretical and 
empirical evidence that the pharmaceutical industry is going through a period of 
transition. It is no longer the case that a few very large companies can dominate 
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the market with a limited number of block buster drugs. Numerous factors, in-
cluding escalating R&D costs, the emergence of competitors in emerging econ-
omies such as Brazil and India; the emergence of generic drug manufacturers 
who can produce for like drugs at the fraction of the cost and a more knowl-
edgeable and demanding consumer/patient; are forcing traditional pharmaceuti-
cal companies to think smarter and re-evaluate their existing supply chains and 
their management. However, it can be said that the biggest issue affecting the 
pharmaceutical industry is worldwide product legislation and licensing, and the 
multiple pieces of differing legislation in place in different countries. These mul-
tiple pieces of legislation create additional procedures and related costs for 
these companies, and subsequently restrict their efficiency and return on in-
vestment.  
 
As the pharmaceutical sector is increasingly more global in its make-up and 
target markets, supply chains, their interlinked activities and management is 
becoming one of the most pressing business issues for pharmaceutical compa-
nies. One of the most pressing issues is partnerships between pharmaceutical 
companies and logistic service providers. It is imperative that there is a clear 
and accepted understanding between all the parties involved and a trust that 
the supply chains will work at all connections in the links, deliver value and meet 
the expectations of the consumer/patient. It was therefore interesting to receive 
Company X’s views on this issue, which supported this opinion. Company X 
stated that without a unified message to suppliers over social and environmen-
tal practices they will not change. Turning hidden costs and risks into competi-
tive advantages through supply base collaboration is of strategic importance, 
and an individual company cannot change an entire culture and infrastructure of 
an industry. In order to induce systemic a change you need to overcome dis-
trust and coalesce with peer companies in areas of mutual interest.  
 
Through the theoretical research conducted as part of this study it is evident 
that this collaborative approach is becoming of increasing strategic importance. 
For example, a number of industry representative bodies, such as the EFPIA, 
has been established and the writing of pan-industry implementation guidance 
on “Pharmaceutical Industry Principles for Responsible Supply Chain Manage-
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ment,” which has been developing through joint working between all of the ma-
jor pharmaceutical companies. 
 
It is also evident that one of the most important benefits resulting from develop-
ing sustainable SCM is delivering value to the customer/end user, and the abil-
ity of getting drugs to the end-user (patient) efficiently, on-time and in perfect 
condition. As ultimately increased customer satisfaction, product innovation, 
and improved reputation are key drivers to future customers and economic 
growth. If the customer is unhappy with a product they will seek an alternative 
from your competitor. 
 
It can therefore be concluded that whilst sustainable SCM is of key importance 
to pharmaceutical companies and they are taking actions to modernise their 
supply and value chains, as a means to deliver cost savings and value to both 
the company and the end-user. It is difficult to foresee totally sustainable SCM 
in the near future unless there is a move towards a global consensus on legisla-
tion on the pharmaceutical industry, using mechanisms such as the World 
Trade Organisation (WTO). 
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Figures 
Figure 1. A comparison between a Value Chain and Supply Chain (Feller et al 
2006) 
 
Figure 2. Simplified Supply Chain 
 
Figure 3. The Three Spheres of Sustainability (Vanderbilt University 2015) 
 
Figure 4. Pharmaceutical Supply Chain (PricewaterhouseCoopers 2011) (2). 
 
Figure 5. Company X typical Supply Chain 
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Tables 
Table 1. The main differences between “commercial” and “clinical” supply 
chains and their value-chain parameters (Rees 2011, p105-110.) 
 
Table 2. A breakdown of the pharmaceutical/drug industry value chain by 
stakeholder (IMS Institute for Healthcare Informatics 2014, p.1-3) 
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Appendix A 
The way to effective and sustainable Supply Chain Manage-
ment in Pharmaceutical Industry 
The objective of this questionnaire is to gain an understanding of the im-
portance of Supply Chain and Value Chain Management within European 
Pharmaceutical Companies, and how it can be used to build a "Sustainable" 
business. 
Company Name 
(Your company legally registered name) 
 
In which country is your company/organization based? 
(Location of registered headquarters) 
 
In what other regions is it mainly active? 
(Where does your company have offices/manufacturing sites outside of the EU) 
Asia 
Africa 
North America 
South America 
Oceania 
Other Europe (Non-EU Members) 
How many people are employed directly by your company? 
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How many people does your company employ directly on Supply Chain 
related issues? 
 
Does your company/organisation have a specialised Supply Chain Man-
agement Team? 
Yes 
No 
N/A 
If "Yes" is your Supply Chain Management coordinated centrally or from 
each of your company's/organisations locations 
 
How many supply chain partners/suppliers does your company interact 
with? 
 
Approximately how much of your Supply Chain Management outsourced 
to 3rd or 4th Party Service Providers? 
(Does your company/organisation employ others to undertake Supply Chain 
functions on your behalf) 
0-25% 
25-50% 
50-75% 
75-100% 
100% 
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If you outsource Supply Chain related activities please provide examples 
of the type of activities. 
 
Are your partners/suppliers required to commit to/apply your own compa-
nies Supply Chain objectives 
Yes 
No 
Please describe briefly a typical Supply Chain in your company 
(This could include a typical Supply Chain in drug production or delivery of a 
product to the end-user) 
 
What are the biggest challenges/obstacles to successful Supply Chain 
Management in the Pharmaceutical Industry? 
 
Please describe briefly how you believe a more sustainable Supply Chain 
can be achieved 
 
How important is sustainability in your companys/organisations Supply 
Chain Management 
(This includes issues such as social responsibility and business efficiency and 
delivery of objectives) 
 
1 2 3 4 5 
 
Not Important      Very Important 
51 
What has been the impact of sustainable and responsible business agen-
da’s and regulatory requirements on your company/organisation and your 
Supply Chains 
 
1 2 3 4 5 
 
Has not impacted at all      Impacted signicantly 
Please describe briefly how you think sustainable and responsible agen-
das can be used as a tool for competitiveness and better Supply Chain 
Management? 
 
What do you/your company/organisation consider to be the most im-
portant payoffs of a more sustainable supply chain 
Financial Payoffs – these include reduced operating costs, increased revenue, 
lower administrative costs 
Customer Related Payoffs – these include increased customer satisfaction, 
product innovation, and improved reputation 
Operational Payoffs – these include process innovation, productivity gains, re-
duced cycle times and waste minimisation 
Organisational Payoffs – these include employee satisfaction, improved stake-
holder relationships, reduced regulatory intervention, reduced risk 
 Other 
If "Other" please specify 
 
What do you believe are Major Drivers and Challenges Facing the Europe-
an Pharmaceutical Industry in the future? 
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Customer Demographic Change 
Resistance to existing diseases and the emergence of new threats 
Investment in Pharmaceutical Research and Development 
Policy Consistency regarding the Pharmaceutical Sector 
Ethical Behaviour 
Increased Competition from Emerging Economies 
Other 
If "Other" please specify 
 
Please add any additional comments you would like to make on how more 
effective and sustainable Supply Chain Management in Pharmaceutical 
Industry can be achieved 
Appendix B 
The way to effective and Sustainable Supply Chain Management in the Euro-
pean Pharmaceutical Industry 
The objective of this questionnaire is to gain an understanding of the im-
portance of Supply Chain and Value Chain Management within European 
Pharmaceutical Industry, and how it can be used to build a "Sustainable" busi-
ness. 
Trade Association full name 
Country of Location 
How many Pharmaceutical Company Members do you have? 
What is the typical size of your Members? 
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(i.e. What is the average number of employees?) 
 
What do you consider to be the biggest challenges/obstacles to success-
ful Supply Chain Management in the Pharmaceutical Industry? 
 
Please describe briefly how you believe a more sustainable Supply Chain 
can be achieved 
What has been the impact of sustainable and responsible business agen-
da’s and regulatory requirements on your members and their Supply 
Chains 
 
1 2 3 4 5 
 
Has not impacted at all      Impacted Significantly 
How important is sustainability in your members Supply Chain Manage-
ment 
(This includes issues such as social responsibility and business efficiency and 
delivery of objectives) 
 
1 2 3 4 5 
 
Not Important      Very Important 
Please describe briefly how you think sustainable and responsible busi-
ness practices andagendas can be used as a tool for competitiveness and 
better Supply Chain Management? 
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What do you/your company/organisation consider to be the most im-
portant payoffs of a more sustainable supply chain 
Financial Payoffs – these include reduced operating costs, increased revenue, 
lower administrative costs 
Customer Related Payoffs – these include increased customer satisfaction, 
product innovation, improved reputation 
Operational Payoffs – these include process innovation, productivity gains, re-
duced cycle times and waste minimisation 
Organisational Payoffs – these include employee satisfaction, improved stake-
holder relationships 
 Other 
If "Other" please specify 
What do you believe are Major Drivers and Challenges Facing the Europe-
an Pharmaceutical Industry in the future? 
Customer Demographic Change 
Resistance to existing diseases and the emergence of new threats 
Investment in Pharmaceutical Research and Development 
Policy Consistency regarding the Pharmaceutical Sector 
Ethical Behaviour 
Increased Competition from Emerging Economies 
 Other 
If "Other" please specify 
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Please add any additional comments you would like to make on how more 
effective and sustainable Supply Chain Management in Pharmaceutical 
Industry can be achieved 
